Kidney international
Audio Summaries

A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease

Jun 19, 2026

The authors aimed to determine whether the somatostatin analogue lanreotide could slow the decline of glomerular filtration rate (GFR) in adults with stage 2/3 autosomal dominant polycystic kidney disease (ADPKD) over three years. The study found that lanreotide did not significantly affect GFR decline compared to placebo, although there was an exploratory signal in creatinine-based estimates that was not corroborated by other measures. Additionally, lanreotide was associated with a higher incidence of gastrointestinal adverse events and hypoglycemia, highlighting the need for careful monitoring in this patient population.

What does it mean to win? Interpreting hierarchical kidney outcomes in hypertension trials

Jun 18, 2026

The authors investigate how hierarchical composite kidney outcomes, analyzed through win statistics, can provide a clearer understanding of kidney health in hypertension trials. They specifically examine the behavior of these outcomes when major kidney events are rare, revealing that the win statistic often reflects kidney function trajectories and is influenced by the measurement and definition of the estimated glomerular filtration rate slope. This study aims to enhance the interpretation of kidney outcomes in clinical trials by addressing limitations of traditional composite endpoints.

A cluster randomized controlled trial (GOAL trial) evaluated a comprehensive geriatric assessment for frail older people with chronic kidney disease

Jun 18, 2026

The GOAL trial aimed to determine whether a comprehensive geriatric assessment (CGA) could enhance patient-centered goal attainment in frail older adults with chronic kidney disease (CKD). Conducted across 15 Australian outpatient centers, the trial found no significant differences in goal attainment or clinical outcomes between those receiving CGA plus usual care and those receiving usual care alone. These results suggest that routine implementation of single-episode outpatient CGA may not be beneficial for this population, highlighting the need for alternative care models.

Asymptomatic serologic reactivation in patients with lupus nephritis in clinical remission: to treat or not to treat?

Jun 18, 2026

The authors examine whether preemptively increasing immunosuppression is more effective than watchful monitoring in patients with lupus nephritis who exhibit asymptomatic serologic reactivation, specifically a rise in anti-double-stranded DNA antibodies. They discuss the findings of a randomized trial by Yap et al. in the context of current treatment strategies and the evolving therapeutic landscape for managing lupus nephritis. The central question is whether proactive treatment is warranted in these patients to prevent potential flares.

Non-invasive quantitative assessment of kidney injury using near-infrared autofluorescence imaging

Jun 18, 2026

The authors investigate the potential of near-infrared (NIR) autofluorescence imaging as a non-invasive method for assessing tubular epithelial cell (TEC) injury in kidney disease, aiming to overcome the limitations of current invasive techniques. Their findings demonstrate that NIR autofluorescence correlates with various markers of kidney injury and can effectively track therapeutic responses in mouse models and human samples. This approach offers a promising avenue for real-time monitoring of kidney health and disease progression.

Resolving the VEGF paradox in DKD: VEGFR1 blockade shows promising renoprotection

Jun 18, 2026

The authors investigate the role of the vascular endothelial growth factor (VEGF) system in the progression of diabetic kidney disease (DKD) and seek to clarify the conflicting data surrounding its modulation. They find that while inhibiting VEGF-A or VEGF receptor 2 worsens kidney damage, blocking VEGF receptor 1 consistently provides renoprotection, suggesting that VEGF receptor 1 inhibition could be a viable therapeutic approach for DKD.

Quantitative Serological Detection of NELL1 Autoantibodies in Membranous Nephropathy

Jun 18, 2026

The authors aimed to develop a high-throughput serological assay for the detection of NELL1 autoantibodies in patients with membranous nephropathy (MN), which is currently diagnosed mainly through invasive methods. They created a luciferase immunoprecipitation system (LIPS) that demonstrated high sensitivity and specificity for identifying NELL1 autoantibodies, suggesting its potential as a noninvasive diagnostic tool and for monitoring disease progression. The study highlights the importance of this assay in improving the clinical management of NELL1-associated MN.

A potential role for effector T cells with Fc receptors in kidney transplant antibody-mediated rejection

Jun 18, 2026

The authors investigate the potential involvement of effector T cells with Fc receptors in the mechanism of antibody-mediated rejection in kidney transplants, a significant contributor to transplant failure. They highlight the established role of natural killer cells and propose that these T cells may also interact with donor-specific antibodies, suggesting a more complex pathogenesis of rejection than previously understood.

Genome-wide Screen Identifies Peroxisomal Role in APOL1 Podocytopathy

Jun 17, 2026

This study investigates how hypoxic stress interacts with APOL1 risk variants G1 and G2 to drive podocyte injury and cell death, particularly in individuals of African ancestry at risk for chronic kidney disease. The authors conducted a genome-wide RNA interference screen, revealing that peroxisomal biogenesis genes significantly influence APOL1-induced cytotoxicity, with impaired peroxisomal function exacerbating cell death. Their findings suggest that enhancing peroxisomal function could be a therapeutic strategy to mitigate podocyte injury and slow CKD progression in genetically susceptible populations.

A pilot study of magnetic resonance fingerprinting and radiomics analysis in autosomal dominant polycystic kidney disease

Jun 16, 2026

This pilot study aimed to investigate whether radiomic features derived from magnetic resonance fingerprinting (MRF) can differentiate between children and young adults with autosomal dominant polycystic kidney disease (ADPKD) and healthy volunteers. The findings revealed that MRF-derived T1 and T2 relaxation times, along with selected radiomic features, significantly distinguished ADPKD patients from healthy individuals, highlighting the potential of MRF in detecting early changes in the non-cystic kidney parenchyma associated with the disease.